Artificial intelligence is showing promise as a second set of eyes in one of medicine's most consequential judgment calls: reading a prostate biopsy.
According to Clinical Lab Products, AI is improving both the accuracy and the efficiency of prostate biopsy review. In practice, that means the software helps pathologists — the doctors who examine tissue samples under a microscope to determine whether cancer is present — do their work more precisely and more quickly.
Prostate biopsy review is painstaking work. A pathologist may sift through many tissue slides looking for small or subtle signs of cancer, and the stakes are high: the reading shapes whether a patient is told they have cancer, how aggressive it appears, and what treatment follows. Small differences in interpretation can lead to very different care decisions.
The reported gains fall into two buckets. Greater accuracy suggests AI can help flag suspicious areas a busy human eye might miss, or add consistency to a process that can vary from reviewer to reviewer. Greater efficiency points to faster turnaround, which matters for labs handling heavy caseloads and for patients waiting anxiously on results.
Clinical Lab Products frames the technology as a tool that supports pathologists rather than a replacement for them — AI surfaces and prioritizes, while the clinician makes the final call.
Why it matters: prostate cancer is one of the most commonly diagnosed cancers in men, so even modest improvements in how biopsies are read could sharpen diagnoses and speed answers for large numbers of patients.